The first denial arrived not with cruelty or malice, but with a phrase so familiar it barely registers as language anymore: “not medically necessary.” The cancer drug, recommended by oncologists and supported by evidence and standard of care, was rejected. No phone call. No physician-to-physician conversation. Just an automated letter and a bureaucratic pause inserted into a life that no longer had room for delay.

The family appealed. They fought. They learned the codes, the timelines, the rituals of escalation. Eventually, the insurer reversed course. The drug was approved. The tumors shrank. What had once been palliative became something else entirely: possibility.

Then came part two: the liver transplant, the only curative option left. And with it, another denial. Again: “not medically necessary.”

This time, the stakes were no longer abstract. This was the difference between progression and survival. Between watching a disease advance and interrupting it. Between a future that could still be imagined and one that was already closing.

To the patient and family, this felt personal. To the insurer, it was procedural. To the system, it was routine.

That disconnect, between lived urgency and institutional logic, is not an accident. It is the defining feature of modern American health care, and it is morally indefensible.

The financial disconnect

According to the National Association of Insurance Commissioners’ 2024 Health Insurance Industry Analysis Report, the U.S. health insurance industry collected nearly $1.2 trillion in premiums in 2024, while paying out rising hospital and medical expenses that pushed the industry’s combined ratio just above 100 percent. Profit margins fell to 0.8 percent, and net income declined sharply from the year before. On paper, this is a story of financial pressure, increased utilization, and tightening margins.

But step outside the spreadsheet, and the story reads very differently.

While insurers emphasize rising costs, they also report $213 billion in capital and surplus, continued dividend payments, and growing investment income. These figures reflect stability, not fragility. They describe an industry under strain, yes, but not one on the brink. And certainly not one forced into denying medically accepted, potentially curative care as a last resort.

Optimized for delay

What patients encounter instead is something else: a system optimized for delay.

Denials are not always permanent. Many are reversed on appeal. Insurers know this. They also know that appeals require time, health literacy, stamina, and often professional advocacy, resources that cancer patients and their families may not have in abundance. The denial, then, becomes a filter. Not of medical necessity, but of persistence. This is not speculation. It is structural behavior.

Insurers hold two contracts simultaneously: one with subscribers, laden with ambiguity and loopholes, and another with shareholders, written with clarity and enforced by regulators. These obligations are not equal, and when they conflict, the hierarchy is clear. Ambiguous phrases like “medical necessity” exist precisely because they can be flexed when margins tighten and utilization rises.

In the NAIC report, utilization is the villain of the year. Hospital and medical expenses rose nearly 9 percent, driven by higher acuity and delayed care finally arriving all at once. But utilization is not a moral failure. It is people finally receiving care they postponed, rationed, or were previously denied. To treat utilization as a threat is to misunderstand health care’s purpose.

For clinicians, this is the familiar moral injury: watching evidence-based care collide with nonclinical gatekeeping. For patients, it feels like abandonment. For families, it feels like betrayal by a system they paid into faithfully, believing, reasonably, that catastrophic illness was precisely what insurance was for.

Stories versus segments

Some observers attribute these denials to algorithms. Others push back, noting that rigid decision trees long predate artificial intelligence. Both can be true. Whether automated or manual, the effect is the same: decisions made far from the bedside, without context, sympathy, or accountability.

What makes the cancer patient’s story so devastating is not just the denial itself, but its timing. The insurer approved the drug that made the transplant possible, then refused the transplant that completed the arc of care. In clinical terms, this is incoherent. In bureaucratic terms, it is perfectly legible: each request evaluated in isolation, divorced from trajectory, prognosis, or prior authorization logic.

Medicine thinks in stories. Insurance thinks in segments.

The NAIC report shows that Medicare remains the most profitable line of business on a per-member basis, while Medicaid and supplemental lines continue to operate at losses. These financial gradients gently shape behavior. Complex, high-cost patients, especially those whose care spans categories, become liabilities to be managed rather than lives to be sustained. And yet, when denials provoke public outrage, insurers often reverse course. Pressure matters. Visibility matters. Stories matter.

The patient in this case will fight again. They have learned how. They will marshal evidence, escalate appeals, and likely win. But that outcome, if it comes, will not redeem the process. It will only confirm the rule: Survival in American health care increasingly depends on one’s ability to contest decisions that should never have been contested in the first place. No one should have to fight cancer and insurance at the same time.

The industry will continue to publish reports, adjust premiums, rebalance risk pools, and explain utilization curves. Those analyses have their place. But they cannot be allowed to obscure the human cost of a system that treats delay as a neutral act. Delay is not neutral in oncology (and it rarely is anywhere else in medicine). It is prognostic.

If health care is to retain any moral coherence, “medical necessity” must once again mean what clinicians understand it to mean: care that meaningfully improves survival, function, or quality of life, based on evidence and expert judgment, not on actuarial anxiety or administrative convenience. Until then, patients will keep telling their stories. Not because they want attention, but because silence is what the system counts on.

And sometimes, telling the story is the only treatment left that hasn’t been denied.

Arthur Lazarus is a former Doximity Fellow, a member of the editorial board of the American Association for Physician Leadership, and an adjunct professor of psychiatry at the Lewis Katz School of Medicine at Temple University in Philadelphia. He is the author of several books on narrative medicine and the fictional series Real Medicine, Unreal Stories. His latest book, a novel, is Against the Tide: A Doctor’s Battle for an Undocumented Patient.